ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

PHASE4CompletedINTERVENTIONAL
Enrollment

1,469

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Copegus

400mg po bid for 16 weeks

DRUG

Copegus

400mg po bid for 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 16 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 24 weeks

Trial Locations (132)

3181

Melbourne

4029

Brisbane

4102

Woolloongabba

5000

Adelaide

10003

New York

10021

New York

10468

The Bronx

11030

Manhasset

11358

Bayside

13285

Marseille

13353

Berlin

13903

Binghamton

14221

Williamsville

15213

Pittsburgh

17033

Hershey

20121

Milan

21201

Baltimore

21205

Baltimore

22042

Falls Church

22902

Charlottesville

23249

Richmond

24105

Kiel

24128

Bergamo

27100

Pavia

27710

Durham

28006

Madrid

28007

Madrid

28034

Madrid

28304

Fayetteville

28677

Statesville

30106

Austell

30309

Atlanta

30625

Hanover

31059

Toulouse

32207

Jacksonville

32209

Jacksonville

32514

Pensacola

32803

Orlando

33136

Miami

33414

Wellington

33612

Tampa

34209

Bradenton

35033

Rennes

35294

Birmingham

36693

Mobile

38138

Germantown

38700

La Tronche

40138

Bologna

40225

Düsseldorf

41013

Seville

44106

Cleveland

46014

Valencia

46202

Indianapolis

48903

Barakaldo

52242

Iowa City

52246

Iowa City

53792

Madison

54511

Vandœuvre-lès-Nancy

55417

Minneapolis

55446

Plymouth

56124

Pisa

61265

Moline

63104

St Louis

66424

Homburg/saar

67091

Strasbourg

70112

New Orleans

70805

Baton Rouge

72205

Little Rock

75203

Dallas

77030

Houston

79106

Freiburg im Breisgau

80120

Littleton

80131

Napoli

82001

Cheyenne

83702

Boise

84121

Salt Lake City

85006

Phoenix

85259

Scottsdale

87108

Albuquerque

90048

Los Angeles

90822

Long Beach

92105

San Diego

92118

Clichy

92123

San Diego

92154

San Diego

93401

San Luis Obispo

94010

Créteil

94115

San Francisco

94121

San Francisco

96817

Honolulu

97220

Portland

98004

Bellevue

98034

Kirkland

98133

Seattle

98195

Seattle

98372

Puyallup

99508

Anchorage

92037-1030

La Jolla

94304-1509

Palo Alto

95825-2115

Sacramento

06030

Farmington

32610-0214

Gainesville

02118

Boston

02720

Boston

01805

Burlington

01655

Worcester

48109-0362

Ann Arbor

48202-2689

Detroit

27599-7584

Chapel Hill

45267-0595

Cincinnati

17604-3200

Lancaster

02920

Cranston

02905

Providence

75235-9151

Dallas

78234-3879

Fort Sam Houston

05009-0001

White River Junction

23320-1706

Chesapeake

99220-3649

Spokane

Unknown

Kingswood

Otahuhu

T6G 2B7

Edmonton

M3N 2V7

Downsview

L5M 2V8

Mississauga

06202

Nice

00716

Ponce

00921-3200

San Juan

00936-5067

San Juan

00909

Santurce

08915

Badalona

08003

Barcelona

08025

Barcelona

08029

Madrid

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00077636 - ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. | Biotech Hunter | Biotech Hunter